Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects
Clinical trial NCT04583228 · COMPLETED
Trial details
- NCT number
- NCT04583228
- Sponsor
- Hengenix Biotech Inc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-08
- Primary completion
- 2021-07-15
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.